France: AI & The Quest for Life Sciences 4.0
With Minister of the Economy and Finance, Bruno Le Maire, emphasizing the importance of “winning the battle on data” and eccentric mathematician Cédric Villani, well in the process of drawing…
Address: 143/147 Bd Anatole France, Saint Denis 93285,France
Tel: +33 (0)1 55 87 30 00
The French Agency for the Safety of Health Products (AFSSAPS) was created by the Act of 1 July 1998 establishing a watchdog and security and safety. This is a public institution under the State supervision of the Ministry of Health. Afssaps’s mission is to ensure job security, quality and proper use of these health products.
Its jurisdiction applies to medicines and raw materials, medical devices and medical devices in vitro diagnostic (or laboratory reagents), for therapeutic products and biological products of human origin (labile blood products, organs, tissues, cells, products of gene and cell therapies), cosmetics and tattoo products.
AFSSAPS is an integeral piece of the public health system. Its activity assessment, monitoring and inspection is based on a high-level expertise to make available health products as safe as possible. It extends into the development and dissemination of information tailored to the needs of health professionals and the public. Moreover, AFSSAPS ensures that each patient receives treated products including pharmaceutical quality, the safety profile and efficacy are demonstrated and validated.
* Public Institution of the State created March 9, 1999, under supervision of the Minister for Health
* A team of nearly a thousand professionals
* More than 2,000 experts meeting in committees and working groups
* Laboratories in Saint-Denis, Lyon and Montpellier
* An operating budget of 109.6 million € for 2009
Pharmacopée
Actualité
Qu’est-ce que la Pharmacopée ?
La Pharmacopée française – 11e édition
Monographies en enquête publique
Réglementation
With Minister of the Economy and Finance, Bruno Le Maire, emphasizing the importance of “winning the battle on data” and eccentric mathematician Cédric Villani, well in the process of drawing…
France – one of the most influential countries in the development of gene therapy– still stands as a global powerhouse in the field, with top-class institutions, a dense network of…
With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These medium-sized national champions form part of G5 Santé, a…
Francois Cornu, president of Eurofins Biomnis, and Gautier Decock, managing director of Eurofins BioPharma Product Testing in France and Belgium, come together to shed light on the company’s unique decentralized…
Nathalie Giraud, director of integrated monitoring investigator services & head of France at PPD, breaks down the strengths and weaknesses of the French clinical trials environment and stresses the importance…
The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain…
Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but…
Iconic French skincare specialist, Pierre Fabre has been enjoying a hot streak of late, with its dermo-cosmetics business registering hefty sales growth of more than EUR 350 (USD 392) million…
Christopher Cuniasse, managing director of Fagron France, sheds light on the specialty area of pharmaceutical compounding and its link with personalized medicine, noting the benefits it can deliver to health…
Éric Ducournau, global CEO of Pierre Fabre Group, the second largest dermo-cosmetic company worldwide and the third-largest French pharmaceutical laboratory, provides insights into the group’s on-going internationalization and its emerging…
Inventiva is a French clinical-stage biotech company focused on developing oral small molecule epigenetic modulators in therapeutic areas with high unmet medical needs such as fibrosis, lysosomal storage disorders and…
Inotrem is a French biotech company developing a novel approach to target inflammatory diseases based on the TREM-1 pathway. Its CEO, Dr Jean-Jacques Garaud explains why he decided to leave…
See our Cookie Privacy Policy Here
